24/7 Wall Street
21 Sept 2026, 15:45 UTC · 1h ago
Verdict
Headline leans bullish. We score MRNA +0.90 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.90strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish · 4 new · 0 priced in
Moderna's Phase 3 adjuvant melanoma study for intismeran autogene was selected for a Presidential Symposium slot at the ESMO congress on October 24.
Newannounced Monday
So whatThe high-profile placement suggests a 'practice-changing' dataset, which could trigger a fundamental re-rating of Moderna's valuation by October 24.
More positive than 99% of claims this week
Continue reading
5 related stories
More positive than 94% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Moderna shares surged 9% to $167.90 on Monday following the symposium announcement.
NewMonday morning trading
More positive than 76% of claims this week
No new efficacy data for the melanoma vaccine was released on Monday.
Newstated as 'No new efficacy data was released Monday'
More negative than 71% of claims this week
Merck (up 1%) and BioNTech (up 2%) showed limited price reaction compared to Moderna.
NewMonday price action
More positive than 40% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
Shares surged 9% after its Phase 3 melanoma study earned a high-profile Presidential Symposium slot, signaling potential practice-changing data.
More positive than 47% of ticker scores this week
Shares rose 2% due to positive platform read-through from Moderna's progress in mRNA cancer immunotherapies.
More positive than 42% of ticker scores this week
The company is a partner in the study and saw a slight 1% gain, though the news is less impactful given its larger oncology franchise.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
11h ago
More positive than 59% of relationship scores this week
[a_to_b] Merck supplies pembrolizumab, the checkpoint inhibitor combined with Moderna's vaccine in the study.
More positive than 39% of relationship scores this week
[mutual] Both companies run individualized messenger RNA cancer immunotherapy programs.
+8.9%
Price agrees with the score
$167.72 vs $154.04 close before publication (Sep 18) · not market-adjusted
MRNA chart →
